Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 30, 2026 08:00 ET | Source: MediciNova, Inc.

MediciNova CEO Provides Shareholder Update

LA JOLLA, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock...
June 30, 2026 07:35 ET | Source: Research and Markets

AI in Pathology Market to Surpass $633.69 Million by 2031: A Comprehensive Segment and Geographic Analysis

Dublin, June 30, 2026 (GLOBE NEWSWIRE) -- The "AI In Pathology - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's...
June 30, 2026 07:33 ET | Source: Research and Markets

Hybrid Professional Development Boosts K-12 Teacher Training Efficiency in 2026

Dublin, June 30, 2026 (GLOBE NEWSWIRE) -- The "K-12 Technology Training For Teachers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ...
June 30, 2026 07:30 ET | Source: InflaRx N.V.

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)The Company is assessing the most efficient...
June 30, 2026 07:30 ET | Source: Pyxis Oncology

Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones

Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap Company now expects updated Phase...
June 30, 2026 07:00 ET | Source: Pasithea

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

Pasithea Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Clinical Activity
June 29, 2026 17:00 ET | Source: Precision Drilling Corporation

Precision Drilling Corporation 2026 Second Quarter Results Conference Call and Webcast

CALGARY, Alberta, June 29, 2026 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) intends to release its 2026 second quarter results after the market closes on Tuesday, July 28, 2026,...
June 29, 2026 16:05 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease

IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA’s decision follows positive Phase 1 results for GT-02287 in both healthy...
June 29, 2026 08:00 ET | Source: Replimune, Inc.

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
June 29, 2026 07:30 ET | Source: Xilio Therapeutics, Inc.

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for...